In conclusion, demographic and clinicopathological features were incorporated from a large population-based cohort to set up an efficient nomogram for predicting the prognosis of female patients suffering from non-metastatic HER2 positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.